氟达拉滨治疗慢性淋巴细胞白血病的疗效及其对生存率的影响  

Effect of fludarabine on treatment of patients with chronic lymphocytic leukemia and its influence on survival rate

作　　者：姜铧[1,2] 龙志国[1,2] 张霞[1,2] 夏云金[1,2] 章正华[1,2] 万楚成[1,2] 

机构地区：[1]湖北医药学院第一临床学院 [2]十堰市太和医院血液内科,湖北十堰442000

出　　处：《实用临床医药杂志》2014年第5期93-95,共3页Journal of Clinical Medicine in Practice

摘　　要：目的探讨氟达拉滨治疗慢性淋巴细胞白血病（CLL）的疗效及其对生存率的影响。方法选取本院血液科收治的老年CLL患者32例，均给予氟达拉滨治疗，并细分为0～Ⅱ期和Ⅲ～Ⅳ期组。另选取30例体检的健康老年患者作为对照组。比较各组患者外周血淋巴细胞亚群数量，分析完全缓解率与临床各相关因素的关系及评价化疗后患者3年的生存率。结果对照组的CD4^＋T细胞数显著高于Ⅲ～Ⅳ期组患者（P〈0．01）；对照组的CD4^＋／CDs^＋值显著高于0～Ⅱ期和Ⅲ～Ⅳ期组患者（P〈0．05）。氟达拉滨治疗后，CLL患者的CD4^＋T和CD4^＋／CD8^＋比值显著升高（P〈0．05）；治疗后完全缓解率与患者的年龄、分期和疗程密切相关；患者的3年存活率为65．6％。结论氟达拉滨能显著改善患者的免疫状态，提高患者的完全缓解率和生存率。Objective To explore the effect of fludarabine on treatment of patients with chronic lymphocytic leukemia （CLL） and its influence on survival rate. Methods 32 elderly patients with CLL were treated with fludarabine, and they were also divided into stage 0- Ⅱ （ n = 17） group and stage Ⅲ～Ⅳ （n = 15） group according to clinical stage of disease. 30 elderly patients with medical examination were designed as control group. Number of peripheral blood lymphocyte were compared between 3 groups, and the relationship between complete remission rate and the clinical related factors as well as survival rate within post - treatment 3 years in CLL patients were observed. Results The number of CD4 ＋ T cells in the control group was significantly higher than that in the stage Ⅲ～Ⅳ group （P〈0.01）. The number of CD4＋/CD8＋ in the control group was significantly higher than that in the treatment group（P 〈 0.05）. There was a close relationship between the complete remission rate of fludarabine treatment and the patient＇s age, staging and course of treatment. The survival rate within post - treatment 3 years was 65.6 %. Conclusion Fludarabine can significantly improve the patients＇ immune status and increase the complete remission rate and survival rate.

关 键 词：氟达拉滨 慢性淋巴细胞白血病 疗效 

分 类 号：R733.7[医药卫生—肿瘤]